NYSE:RCUS

Arcus Biosciences Stock Forecast, Price & News

$31.41
-1.56 (-4.73 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.36
$33.27
50-Day Range
$22.75
$33.89
52-Week Range
$16.69
$42.36
Volume308,416 shs
Average Volume586,483 shs
Market Capitalization$2.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.16
30 days | 90 days | 365 days | Advanced Chart
Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Arcus Biosciences logo

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

487th out of 2,220 stocks

Pharmaceutical Preparations Industry

240th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Arcus Biosciences?

Wall Street analysts have given Arcus Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcus Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Arcus Biosciences
.

How can I listen to Arcus Biosciences' earnings call?

Arcus Biosciences will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($1.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.22. The business earned $9.46 million during the quarter, compared to analyst estimates of $18.80 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 196.76%.
View Arcus Biosciences' earnings history
.

How has Arcus Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCUS stock has increased by 85.1% and is now trading at $31.41.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RCUS?

8 brokers have issued 12 month target prices for Arcus Biosciences' shares. Their forecasts range from $28.40 to $70.00. On average, they expect Arcus Biosciences' stock price to reach $50.55 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 61, Pay $326.82k)
  • Ms. Jennifer Jarrett M.B.A., COO & Director (Age 50, Pay $603.17k)
  • Dr. William J. Grossman, Chief Medical Officer (Age 50, Pay $708.8k)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 63)
  • Mr. Robert C. Goeltz II, Principal Financial & Accounting Officer and CFO (Age 48)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 52)
  • Ms. Katherine Bock, VP of Investor Relations & Corp. Strategy
  • Ms. Carolyn C. Tang, Gen. Counsel & Corp. Sec.
  • Ms. Yvonne Gehring, VP of HR & Operations
  • Dr. Jay P. Powers, Sr. VP of Drug Discovery (Age 55)

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.07%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Tarbox Family Office Inc. (0.00%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences
.

Which institutional investors are buying Arcus Biosciences stock?

RCUS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Tarbox Family Office Inc., and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $31.41.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $2.23 billion and generates $77.52 million in revenue each year. The company earns $-122,860,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 236 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

Where are Arcus Biosciences' headquarters?

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.